TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – [...]

By |2019-07-03T14:56:47+02:00October 15th, 2013|Publication, TG1050|Comments Off on TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – [...]

By |2019-07-03T11:43:30+02:00October 15th, 2013|TG1050|Comments Off on TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.

Houda Boukhebza, et al. Journal of Hepatology, 2013, (58), Supplement [...]

By |2019-07-03T12:12:48+02:00September 3rd, 2013|Publication, TG1050|Comments Off on Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.

130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.

Perrine Martin, et al. Journal of Hepatology, 2013, (58), Supplement [...]

By |2019-07-03T12:18:43+02:00September 3rd, 2013|Publication, TG1050|Comments Off on 130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.

Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)

link J. Heo, C. Breitbach, M. Cho, T.H. Hwang, C.W. [...]

By |2019-05-25T10:12:33+02:00May 20th, 2013|Pexa-Vec, Publication|Comments Off on Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)

link J. Lee J, S.Y. Park, J. Burke, H.Y. Lim, [...]

By |2019-05-27T14:25:36+02:00May 20th, 2013|Pexa-Vec, Publication|Comments Off on Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
Go to Top